AbbVie Inc (ABBV)
170.83
-1.91
(-1.11%)
USD |
NYSE |
Jun 26, 10:57
AbbVie SG&A Expense (TTM): 13.15B for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 13.15B |
December 31, 2023 | 12.87B |
September 30, 2023 | 13.10B |
June 30, 2023 | 13.03B |
March 31, 2023 | 15.17B |
December 31, 2022 | 15.26B |
September 30, 2022 | 15.10B |
June 30, 2022 | 14.88B |
March 31, 2022 | 12.63B |
December 31, 2021 | 12.35B |
September 30, 2021 | 12.32B |
June 30, 2021 | 12.08B |
March 31, 2021 | 12.45B |
December 31, 2020 | 11.30B |
September 30, 2020 | 10.02B |
June 30, 2020 | 8.83B |
March 31, 2020 | 6.957B |
December 31, 2019 | 6.942B |
September 30, 2019 | 6.92B |
June 30, 2019 | 7.182B |
March 31, 2019 | 7.288B |
December 31, 2018 | 7.399B |
September 30, 2018 | 7.426B |
June 30, 2018 | 6.964B |
March 31, 2018 | 6.713B |
Date | Value |
---|---|
December 31, 2017 | 6.295B |
September 30, 2017 | 6.018B |
June 30, 2017 | 5.942B |
March 31, 2017 | 5.899B |
December 31, 2016 | 5.881B |
September 30, 2016 | 5.939B |
June 30, 2016 | 6.032B |
March 31, 2016 | 6.269B |
December 31, 2015 | 6.387B |
September 30, 2015 | 7.991B |
June 30, 2015 | 8.112B |
March 31, 2015 | 7.857B |
December 31, 2014 | 7.724B |
September 30, 2014 | 5.831B |
June 30, 2014 | 5.497B |
March 31, 2014 | 5.455B |
December 31, 2013 | 5.352B |
September 30, 2013 | 5.315B |
June 30, 2013 | 5.139B |
March 31, 2013 | 4.979B |
December 31, 2012 | 4.989B |
September 30, 2012 | 4.712B |
June 30, 2012 | 6.168B |
March 31, 2012 | 5.963B |
December 31, 2011 | 5.894B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
6.92B
Minimum
Sep 2019
15.26B
Maximum
Dec 2022
11.63B
Average
12.40B
Median
SG&A Expense (TTM) Benchmarks
Johnson & Johnson | 21.93B |
Eli Lilly and Co | 6.912B |
Pfizer Inc | 14.85B |
Bristol-Myers Squibb Co | 8.377B |
Merck & Co Inc | 10.51B |